MannKind Corporation Showcases Innovations in Inhaled Insulin
Exploring Advancements in Inhaled Insulin by MannKind Corporation
DANBURY, Conn. and WESTLAKE VILLAGE, Calif. — MannKind Corporation (NASDAQ: MNKD), dedicated to developing innovative inhaled therapeutic products, is set to showcase significant advancements in inhaled insulin at the American Diabetes Association's 85th Scientific Sessions. This prestigious event will occur in Chicago, and from June 20-23, MannKind aims to highlight its groundbreaking approach to diabetes care.
MannKind’s Research Focus
During the conference, Dr. Michael J. Haller, a leading expert in pediatric endocrinology, will discuss findings from the INHALE-1 clinical trial for Afrezza, MannKind's patented inhaled insulin product. His presentation during the “Future Ready” symposium will cover recent breakthroughs in inhaled insulin for treating Type 1 diabetes in children aged 4-17.
Symposium Highlights
The Future Ready symposium promises to be a cornerstone of the meeting. Scheduled for Sunday, June 22, from 1:30 to 3:00 p.m. (Central) in Room W 181(A-C), Dr. Haller's presentation titled "From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment" will showcase comprehensive data and insights into the clinical applications of Afrezza.
Engagement with the Community
MannKind invites attendees to visit booth #1617, where the Medical Education Team will engage in scientific discussions and provide detailed information regarding MannKind's products and innovations. This booth will be a hub for learning about the newest developments in inhaled insulin.
Key Research Presentations
The company will also feature significant poster presentations, including:
- Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1)
Presented by Dr. Peter Calhoun on Saturday, June 21, from 12:30 to 1:30 p.m. (Central). - Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo
This will cover results from a Phase III Clinical Trial conducted in India, presented by Dr. K M Prasanna Kumar, scheduled for the same time on June 21.
Future Developments in Pediatric Indications
MannKind aims to release topline results from a full study of pediatric data alongside safety extensions in the upcoming quarters. The anticipated timeline suggests that a Supplemental Biologics License Application (sBLA) will be submitted mid-year for the pediatric indication of Afrezza.
About MannKind Corporation
Dedicated to addressing unmet medical needs, MannKind Corporation (NASDAQ: MNKD) continues to innovate in inhaled therapeutic products. The company is focused on improving treatment options for conditions such as diabetes and various lung diseases through advanced inhalation devices. Their unique delivery system provides medication to the deep lung efficiently, presenting both local and systemic effects as needed.
MannKind's mission is driven by a team of passionate professionals committed to transforming the health of individuals living with chronic conditions. By leveraging their expertise in formulation and engineering, MannKind is transforming patient care and medication delivery.
Frequently Asked Questions
What is MannKind Corporation known for?
MannKind Corporation specializes in developing and commercializing inhaled therapeutic products aimed at treating serious endocrine and orphan lung diseases.
When and where will the ADA Scientific Sessions take place?
The 85th Scientific Sessions will be held in Chicago from June 20-23.
Who is Dr. Michael J. Haller?
Dr. Haller is the Chief of Pediatric Endocrinology at the University of Florida and is leading MannKind's clinical trial for Afrezza in pediatric patients.
What is Afrezza?
Afrezza is an inhaled insulin product designed to provide rapid control for blood sugar levels in diabetic patients.
How does MannKind engage with the medical community?
MannKind hosts booths at scientific conferences and engages in discussions about their innovations and findings.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.